Nova Patents
AT368458T

CHRONIC, BOLUS ADMINISTRATION OF D-threo METHYLPHENIDATE

Abstract

The use of methylphenidate comprising at least 95% of D-threo methylphenidate or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating at least one disorder, attention deficit hyperactivity disorder, attention deficit or dementia associated with AIDS by administration as a single event, excluding sustained release, time release and pulsed release, in each twenty four hour period over a time period of at least several weeks.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Granted
  4. Today

92 members in 17 offices

This recordMember, by publication datePriority claim7 more offices are in the list below

Priority claims1

Priority claims
DocumentOfficeKindDate
93768497United States of AmericaA

Members92

Family members, oldest first
DocumentOfficeKind
US5733756AUnited States of AmericaA
US5837284AUnited States of AmericaA
CA2240329A1CanadaA1
CA2465077A1CanadaA1
WO9903471A1World Intellectual Property Organization (WIPO)A1
AU7834398AAustraliaA
CA2241611A1CanadaA1
CA2468370A1CanadaA1
WO9916439A1World Intellectual Property Organization (WIPO)A1
AU7976598AAustraliaA
US5908850AUnited States of AmericaA
US5922736AUnited States of AmericaA
EP1001772A1European Patent Office (EPO)A1
EP1032389A1European Patent Office (EPO)A1
DE1001772T1GermanyT1
ES2153338T1SpainT1
IL135288D0IsraelD0
US6255325B1United States of AmericaB1
AU738521B2AustraliaB2
AU738744B2AustraliaB2
US2001041717A1United States of AmericaA1
US2002022640A1United States of AmericaA1
US6355656B1United States of AmericaB1
US2002035126A1United States of AmericaA1
JP2002510318AJapanA
EP1032389A4European Patent Office (EPO)A4
EP1001772A4European Patent Office (EPO)A4
US6486177B2United States of AmericaB2
US2002198234A1United States of AmericaA1
CA2453510A1CanadaA1
WO03005962A2World Intellectual Property Organization (WIPO)A2
AU2002318302C1AustraliaC1
US6528530B2United States of AmericaB2
NZ503571ANew ZealandA
WO03005962A3World Intellectual Property Organization (WIPO)A3
US2003113373A1United States of AmericaA1
US6602887B2United States of AmericaB2
US6635284B2United States of AmericaB2
US2003232857A1United States of AmericaA1
KR20040029360ARepublic of KoreaA
EP1411943A2European Patent Office (EPO)A2
MXPA04000249AMexicoA
US2004091532A1United States of AmericaA1
IL159313D0IsraelD0
CA2241611CCanadaC
US2004204456A1United States of AmericaA1
CA2240329CCanadaC
US2005049279A1United States of AmericaA1
US2005119307A1United States of AmericaA1
EP1541147A1European Patent Office (EPO)A1
JP2005520780AJapanA
EP1411943A4European Patent Office (EPO)A4
EP1001772B1European Patent Office (EPO)B1
AT306266TAustriaT
ATE306266T1AustriaT1
EP1607093A1European Patent Office (EPO)A1
US2006030587A1United States of AmericaA1
HK1077501A1Hong Kong, ChinaA1
DK1001772T3DenmarkT3
DE69831869D1GermanyD1
ES2153338T3SpainT3
DE69831869T2GermanyT2
US2006183774A1United States of AmericaA1
US7115631B2United States of AmericaB2
AU2002318302B2AustraliaB2
IL135288AIsraelA
EP1032389B1European Patent Office (EPO)B1
AT368458TThis recordAustriaT
ATE368458T1AustriaT1
PT1032389EPortugalE
DE69838179D1GermanyD1
EP1844777A1European Patent Office (EPO)A1
DK1032389T3DenmarkT3
ES2289787T3SpainT3
DE69838179T2GermanyT2
NZ530211ANew ZealandA
EP1032389B8European Patent Office (EPO)B8
US7431944B2United States of AmericaB2
CA2468370CCanadaC
US2009088455A1United States of AmericaA1
NZ565754ANew ZealandA
US2010035928A1United States of AmericaA1
US2010093797A1United States of AmericaA1
JP2010265299AJapanA
CA2465077CCanadaC
US2011201645A1United States of AmericaA1
US2011257227A1United States of AmericaA1
CA2453510CCanadaC
US2013053414A1United States of AmericaA1
CY1107748T1CyprusT1
US2013109719A1United States of AmericaA1
JP5412700B2JapanB2